Executive Summary
Drug development is becoming increasingly data-driven, computational, and personalized. Yet pharmaceutical companies still rely heavily on physical experiments and clinical trials to evaluate drug candidates and understand how therapies behave.
Digital twins offer a way to complement that traditional approach.
A digital twin is a virtual representation of a real-world system that is continuously informed by data. In pharmaceuticals, digital twins can represent molecules, biological processes, patients, clinical trials, manufacturing systems, and other elements of the development lifecycle.
The goal is not to create a perfect virtual copy of a patient or replace clinical research. Instead, digital twins can help researchers simulate scenarios, identify patterns, predict outcomes, and determine which physical experiments are most valuable.
Combined with artificial intelligence, computational biology, and real-world evidence, digital twins could create a continuous feedback loop between virtual modeling and real-world experimentation.
For pharmaceutical companies, the opportunity is significant: better decisions, more targeted experimentation, improved clinical development, and more predictive operations.
Why Does Drug Development Need Better Simulation?
Drug development is fundamentally an experimentation process.
Researchers develop hypotheses, conduct experiments, analyze results, and determine what to test next. While this approach remains essential, it can require years of work and substantial investment.
Drug candidates may fail because of efficacy, safety, pharmacokinetics, manufacturing challenges, or other factors that become apparent only after significant resources have been committed.
Digital twins introduce another layer of intelligence. Instead of relying exclusively on physical experiments to explore every possibility, researchers can use virtual models to examine selected scenarios first.
The objective is not to eliminate experimentation. It is to make physical experimentation more targeted, efficient, and informative.
How Could Digital Twins Transform Drug Discovery?
Drug discovery requires researchers to explore enormous chemical and biological spaces.
Digital models can help simulate how potential compounds may behave before every candidate is synthesized and tested. Combined with AI, digital twins could support target validation, molecular optimization, drug-target interaction modeling, toxicity assessment, and pharmacokinetic prediction.
AI can identify promising candidates, while digital models can simulate their potential behavior under different conditions.
This could help researchers narrow the number of compounds requiring physical testing and direct laboratory resources toward candidates with greater potential.
The broader opportunity is to move from testing large numbers of possibilities toward intelligently selecting which candidates deserve physical experimentation.
How Could Digital Twins Improve Clinical Trials?
Clinical development presents another major opportunity.
Trial outcomes are influenced by patient characteristics, disease progression, treatment response, adherence, site performance, and protocol design.
Digital twins could help researchers model some of these variables before and during clinical development.
Potential applications include:
- Trial design and optimization
- Patient stratification
- Enrollment forecasting
- Dose selection
- Endpoint modeling
- Site selection
- Outcome prediction
By modeling different scenarios, sponsors could identify potential weaknesses in trial designs before they become costly operational problems.
Digital twins could therefore become another tool for improving trial planning and reducing uncertainty.
Could Digital Twins Support Precision Medicine?
One of the most ambitious applications is the patient-level digital twin.
Such a model could potentially combine genomic information, clinical history, imaging, laboratory results, treatment history, and physiological measurements.
The objective would be to develop a dynamic representation that helps predict how an individual might respond to different interventions.
This could eventually support more personalized treatment strategies and better-informed clinical decisions.
However, patient-level digital twins remain an emerging field. Human biology is extraordinarily complex, and current models cannot reproduce an individual’s physiology perfectly.
Their near-term role is therefore more likely to involve supporting prediction and decision-making rather than replacing clinical judgment or clinical trials.
Why Could Manufacturing Be an Early Opportunity?
Pharmaceutical manufacturing may provide some of the most practical applications for digital twins.
Modern facilities generate large amounts of data from equipment, sensors, laboratories, production systems, and quality processes.
A digital twin can represent manufacturing processes and simulate different operating conditions. Companies could use these models to evaluate equipment performance, process changes, production constraints, maintenance scenarios, and quality risks.
Instead of discovering problems after they affect production, manufacturers could potentially identify risks through simulation.
This supports a shift from reactive manufacturing toward predictive operations.
How Could Digital Twins Strengthen Quality Management?
Quality management is another promising application.
Pharmaceutical companies need to understand how changes in equipment, materials, processes, or environmental conditions could affect product quality.
Digital twins can provide a controlled environment for evaluating potential changes before implementation.
They could support deviation investigations, root-cause analysis, process optimization, continuous process verification, and quality risk management.
This could allow organizations to evaluate more scenarios while reducing unnecessary disruption to physical operations.
Why Will AI and Digital Twins Work Together?
Digital twins and AI are complementary technologies.
AI can identify patterns, generate predictions, and learn from large datasets. Digital twins can provide an environment where those predictions can be evaluated through simulation.
Together, they can create a continuous learning cycle:
Real-world data → AI models → Digital simulation → Decision → Physical action → New data
Every experiment or operational event can generate additional information that improves future models.
This combination could become increasingly important as pharmaceutical organizations move toward predictive research and development.
What Role Will Real-World Evidence Play?
Digital twins depend on high-quality data.
The growth of real-world evidence could accelerate their development. Electronic health records, patient registries, claims data, wearable devices, imaging, laboratory measurements, and patient-generated information can provide additional inputs for increasingly sophisticated models.
However, more data does not automatically produce better digital twins.
Data quality, interoperability, representativeness, privacy, and governance will determine whether these models can be trusted.
Pharmaceutical companies will therefore need strong data foundations before digital twins can deliver their full potential.
Will Regulators Accept Digital Twins?
Regulatory acceptance will be critical.
Digital models may eventually support aspects of drug development, but regulators will need confidence in their scientific validity.
Important questions include how digital twins should be validated, how model uncertainty should be measured, when simulated evidence can complement physical evidence, and how frequently models should be updated.
Digital twins are unlikely to eliminate traditional clinical evidence in the foreseeable future. Their regulatory role will likely expand gradually as validation methodologies and scientific confidence mature.
What Should Pharma Leaders Do Now?
Pharmaceutical companies do not need to wait for perfect digital twins before exploring their potential.
Leaders should begin with clearly defined use cases where the technology can deliver measurable value. Manufacturing processes, molecular modeling, clinical trial operations, and specific disease models may offer more immediate opportunities than attempting to model an entire human being.
Companies should also invest in interoperable data infrastructure, establish model validation frameworks, and develop capabilities that combine AI with simulation.
Where digital models could influence clinical evidence or development decisions, early regulatory engagement will be important.
What Will the Future of Digital Twins Look Like?
The long-term vision is a pharmaceutical development environment in which virtual and physical experimentation operate together.
Researchers could simulate molecules before synthesis. Clinical teams could model trial scenarios before enrollment. Manufacturers could test process changes before implementation. Scientists could use increasingly sophisticated patient models to explore treatment responses.
Every physical experiment could generate new data that improves the corresponding digital model.
This could create a continuous learning system across the drug development lifecycle.
The result would not be a purely virtual pharmaceutical industry. It would be a hybrid development model in which simulation helps determine where physical experimentation can deliver the greatest value.
Conclusion
Digital twins could become an important component of the next generation of pharmaceutical development.
Their greatest value may not come from creating perfect virtual copies of molecules, patients, or clinical trials. Instead, their potential lies in helping researchers explore complex scenarios before committing significant time and resources to physical experimentation.
Combined with AI, real-world evidence, computational biology, and connected data infrastructure, digital twins could make drug development more predictive, targeted, and adaptive.
Significant challenges remain around biological complexity, data quality, validation, interoperability, privacy, and regulatory acceptance.
But the direction is increasingly clear.
The future of drug development will not be purely physical or purely digital. It will increasingly combine real-world experimentation with intelligent virtual models that help pharmaceutical companies determine what to test, where to test it, and how to learn faster from every result.
Digital twins are emerging as an important technology in Drug Development, creating virtual representations of patients, biological systems, processes, or other physical entities. These models can combine clinical information, mathematical modeling, machine learning, and other data sources to simulate potential outcomes and support research decisions. A 2026 review describes applications across the pharmaceutical value chain, from target discovery and preclinical research through clinical trials, regulatory review, manufacturing, and post-market care.
Digital Twins and Drug Development
In Drug Development, a digital twin can represent a biological system or individual patient using continuously updated data. The model can then be used to explore different scenarios, potentially helping researchers understand how diseases progress or how treatments could affect different patients.
Artificial intelligence and machine learning can make digital twins more sophisticated. In Drug Development, AI can help analyze complex datasets and improve predictive models, while digital twins provide a structured environment for applying those predictions to biological or clinical scenarios.
Drug Development and Manufacturing
Digital twins are also being explored beyond clinical research. In pharmaceutical manufacturing, virtual models can support real-time monitoring, predictive analytics, process optimization, and preventive maintenance. These capabilities could improve production efficiency and product quality throughout the Drug Development lifecycle.
Drug Development and Rare Diseases
Rare-disease research presents unique challenges because patient populations can be small and clinical data may be limited. Digital twins could help researchers model disease progression and explore treatment strategies using available patient-level information, potentially supporting more efficient Drug Development approaches.
Challenges for Drug Development Digital Twins
Despite their potential, digital twins remain an emerging technology in Drug Development. Researchers must address data integration, model accuracy, validation, privacy, interoperability, and regulatory acceptance before these systems can become widely used as evidence-generating tools.
Biological systems are also highly complex. Creating a reliable virtual representation of an individual patient requires diverse, high-quality data and models that can accurately capture changing biological conditions.
Future of Drug Development With Digital Twins
The future of Drug Development could involve closer integration between digital twins, AI, real-world data, clinical trials, and precision medicine. As modeling techniques and data infrastructure improve, digital twins may become valuable tools for testing hypotheses, designing studies, optimizing treatments, and supporting manufacturing decisions.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
